Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial

The Lancet Oncology

Volumn 16, Issue 7, 2015, Pages 763-774

  Thatcher, Nick ^a   Hirsch, Fred R ^b   Luft, Alexander V ^c   Szczesna, Aleksandra ^d   Ciuleanu, Tudor E ^e   Dediu, Mircea ^f   Ramlau, Rodryg ^g   Galiulin, Rinat K ^h   Bálint, Beatrix ⁱ   Losonczy, György ^j   Kazarnowicz, Andrzej ^k   Park, Keunchil ^l   Schumann, Christian ^m,n   Reck, Martin ^o   Depenbrock, Henrik ^p   Nanda, Shivani ^q   Kruljac Letunic, Anamarija ^p   Kurek, Raffael ^p   Paz Ares, Luis ^r   Socinski, Mark A ^s  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c Leningrad Regional Clinical Hospital   (Russian Federation)

^d Regional Lung Diseases Hospital   (Poland)

^e IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^f Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti   (Romania)

^g POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^h Omsk Regional Oncology Center   (Russian Federation)

ⁱ Csongrád County Hospital of Chest Diseases   (Hungary)

^j SEMMELWEIS UNIVERSITY   (Hungary)

^k Independent Public Center of Tuberculosis and Lung Diseases   (Poland)

^l Samsung Medical Center   (South Korea)

^m UNIVERSITY HOSPITAL ULM   (Germany)

ⁿ Clinic Kempten Oberallgaeu   (Germany)

^o Member of the German Center for Lung Research   (Germany)

^p LILLY DEUTSCHLAND GMBH   (Germany)

^q ELI LILLY AND COMPANY   (United States)

^r UNIVERSITY OF SEVILLE   (Spain)

^s UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; NECITUMUMAB; ANTINEOPLASTIC AGENT; GENTAMICIN; IMC-11F8 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTERIAL THROMBOEMBOLISM; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; FATIGUE; FEMALE; FOLLOW UP; GEOGRAPHY; HUMAN; HYPERSENSITIVITY; HYPOMAGNESEMIA; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SQUAMOUS NON SMALL CELL LUNG CANCER; TELEPHONE; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; VERY ELDERLY; AGE; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEX DIFFERENCE; SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENTAMICINS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SEX FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84937518476     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00021-2     Document Type: Article

References (43)

1. Perez-Moreno P, Brambilla E, Thomas R, Soria JC Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012, 18:2443-2451.
2. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 2014, 14:535-546.
3. Gandara DR, Hammerman PS, Sos ML, Lara PN, Hirsch FR Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res 2015, 21:2236-2243.
4. Besse B, Adjei A, Baas P, et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol 2014, 25:1475-1484.
5. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
6. Cohen MH, Cortazar P, Justice R, Pazdur R Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). Oncologist 2010, 15:1352-1358.
7. Cohen MH, Gootenberg J, Keegan P, Pazdur R FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007, 12:713-718.
8. Cohen MH, Justice R, Pazdur R Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. Oncologist 2009, 14:930-935.
9. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013, 31:2895-2902.
10. Cooper WA, Lam DC, O'Toole SA, Minna JD Molecular biology of lung cancer. J Thorac Dis 2013, 5(suppl 5):S479-S490.
11. Kerr KM, Bubendorf L, Edelman MJ, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 2014, 25:1681-1690.
12. Leighl NB, Rekhtman N, Biermann WA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology guideline. J Clin Oncol 2014, 32:3673-3679.
13. Gerber DE, Gandhi L, Costa DB Management and future directions in non-small cell lung cancer with known activating mutations. Am Soc Clin Oncol Educ Book 2014, e353-e365.
14. Rose-James A, Sreelekha T Molecular markers with predictive and prognostic relevance in lung cancer. Lung Cancer Int 2012, 2012. Article ID 729532.
15. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012, 18:1167-1176.
16. Spigel DR, Reckamp KL, Rizvi NA, et al. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2015, 33(suppl). abstr 8009.
17. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014, 384:665-673.
18. Stinchcombe TE, Socinski MA Considerations for second-line therapy of non-small cell lung cancer. Oncologist 2008, 13(suppl 1):28-36.
19. Lopez-Malpartida AV, Ludena MD, Varela G, Garcia Pichel J Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas. Lung Cancer 2009, 65:25-33.
20. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
21. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
22. Toschi L, Cappuzzo F Gemcitabine for the treatment of advanced nonsmall cell lung cancer. Onco Targets Ther 2009, 2:209-217.
23. Samakoglu S, Deevi DS, Li H, et al. Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC. Cancer Genomics Proteomics 2012, 9:77-92.
24. Paz-Ares L, Mezger J, Ciuleanu TE, et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol 2015, 16:328-337.
25. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A AJCC cancer staging manual 2010, Springer, New York. seventh edition.
26. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
27. Hollen PJ, Gralla RJ, Kris MG, et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 1994, 73:2087-2098.
28. Nord E EuroQol: health-related quality of life measurement. Valuations of health states by the general public in Norway. Health Policy 1991, 18:25-36.
29. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012, 13:33-42.
30. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807.
31. Schoenfeld DA The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika 1981, 68:316-319.
32. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
33. Hochberg Y A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75:800-802.
34. Kuenen B, Witteveen PO, Ruijter R, et al. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res 2010, 16:1915-1923.
35. Reck M, Socinski MA, Luft A, et al. Quality-of-life (QoL), tolerability, and supportive care results: necitumumab phase 3 SQUIRE study. Ann Oncol 2014, 25(supplement 4):iv426-iv470.
36. Thatcher N, Ciuleanu TE, Ramlau R, et al. Subgroup analysis of elderly patients in SQUIRE: a randomized, multicenter, open-label, phase III study of necitumumab (N) plus gemcitabine-cisplatin (GC) chemotherapy versus GC alone in first-line treatment of patients (PTS) with stage IV squamous non-small cell lung cancer (SQ-NSCLC). Ann Oncol 2015, 26(supplement 1):i29-i44.
37. Li S, Kussie P, Ferguson KM Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure 2008, 16:216-227.
38. Pujol JL, Pirker R, Lynch TJ, et al. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer 2014, 83:211-218.
39. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf 2012, 11(suppl 1):S9-19.
40. Segaert S, Van Cutsem E Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005, 16:1425-1433.
41. Petrelli F, Cabiddu M, Borgonovo K, Barni S Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol 2012, 23:1672-1679.
42. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009, 158:1-9.
43. Song X, Long SR, Barber B, et al. Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer. Curr Clin Pharmacol 2012, 7:56-65.